IGBA joins the Fight the Fakes Alliance (December 2022)
Fight the Fakes Alliance calls for a watertight global medicines supply chain.
IGBA Reiterates its Yearly Call to Join the Biosimilars Movement on Advancing Access (November 2022)
Geneva, November 14, 2022 – In the week ahead, IGBA will renew its commitment to the collaborative effort to establish worldwide biosimilar policies that deliver better health outcomes and biologics access equity for more patients. The third Global Biosimilars Week will run from 14th to 18th November, 2022 on social media, supported by a rich resource dedicated website globalbiosimilarsweek.org.
IGBA’s CEO Advisory Committee Meets with WHO Director General and WHO Leadership (October 2022)
The International Generic and Biosimilar Medicines Association’s (IGBA) newly established CEO Advisory Committee held its first in-person meeting in Geneva this week and had a far-reaching exchange with the World Health Organization’s (WHO) Director-General Dr. Tedros Adhanom Ghebreyesus and other WHO leaders. This was the first opportunity for Dr. Tedros to engage in a direct dialogue with the IGBA CEO Advisory Committee following its launch and the admission of IGBA as a non-State actor in official relations with WHO earlier this year.
More Articles...
- Richard Saynor and Vinita Gupta appointed Chair and Vice-Chair of IGBA CEO Advisory Committee (October 2022)
- Global Biosimilars Week: Message of Vivian Frittelli, Chair, IGBA (October 2022)
- WHO-South Korea biomanufacturing training hub initiative (September 2022)
- Generic and Biosimilar Medicines, Central to Patient Health and Global Healthcare Policies (September 2022)
